Your shopping cart is currently empty

ZLMT-12 (compound 35) is a tacrine derivative and a potent inhibitor of CDK2 (IC50: 0.011 μM) and CDK9 (IC50: 0.002 μM). ZLMT-12 weakly inhibits AChE (IC50: 19.023 μM) and BuChE (IC50: 2.768 μM). ZLMT-12 has anti-proliferative activity and low cytotoxicity. ZLMT-12 blocks the cell cycle in S-phase and G2/M-phase and induces apoptosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,520 | 10-14 weeks | 10-14 weeks | |
| 50 mg | $1,980 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $2,500 | 10-14 weeks | 10-14 weeks |
| Description | ZLMT-12 (compound 35) is a tacrine derivative and a potent inhibitor of CDK2 (IC50: 0.011 μM) and CDK9 (IC50: 0.002 μM). ZLMT-12 weakly inhibits AChE (IC50: 19.023 μM) and BuChE (IC50: 2.768 μM). ZLMT-12 has anti-proliferative activity and low cytotoxicity. ZLMT-12 blocks the cell cycle in S-phase and G2/M-phase and induces apoptosis. |
| Targets&IC50 | AChE:19.023 μM, CDK2:0.011 μM, CDK9:0.002 μM, BChE:2.768 μM |
| Molecular Weight | 479.02 |
| Formula | C26H31ClN6O |
| Smiles | #N/A |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.